01548.HK
Genscript Biotech Corporation
HKSE · Healthcare · Biotechnology · CN
HKD 37.70
+2.72%Year over year
Reported trailing growth
- Revenue
- +1.9%
- EBITDA
- -12.9%
- EBIT
- -30.0%
- EPS
- —
- Free cash flow
- -74.9%
- Operating cash flow
- -35.7%
Forward estimates
Based on analyst estimates
- Revenue
- -41.2%
- EBITDA
- -62.4%
- EPS
- +103.4%
Three-year CAGR
- Revenue
- +15.3%
- EBITDA
- +81.2%
- EBIT
- +212.2%
- Net income
- —
- EPS
- —
- Free cash flow
- +434.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026